NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib
NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...
Post Independent Citizen Telegram3 天Opinion
Doctor’s Tip: Cholesterol — we need some but too much is harmful
This column is the first in a series about risk factors for atherosclerosis (hardening of the arteries), the cause of several ...
How drugs like Wegovy might affect kids in the long term
The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...
来自MSN4 天
The Scary Ozempic Side Effect No One's Talking About—and What You Can Do
Ozempic is often hailed as a wonder drug, but like any other medication, it’s not perfect. People have reported mild side ...
Taiwan News5 天
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and ...
Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected ...
FDA accepts lerodalcibep application to lower LDL cholesterol
LIB Therapeutics announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA ...
Kentucky Lantern5 天
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about ...
As Kentucky's high rate of diabetes pushes up use of GLP-1 weight-loss drugs, University of Louisville researchers look at ...